ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit

ADMA Biologics faces a securities fraud class action lawsuit after Culper Research alleged the company engaged in channel stuffing to artificially inflate 2025 revenue growth from -3% to reported +20%. The allegations triggered a 29% stock decline, with the largest single-day drop of 16.6% on March 24, 2026. Investors have until August 10, 2026, to request lead plaintiff status.